Modern iron replacement therapy: clinical and pathophysiological insights.

Modern iron replacement therapy: clinical and pathophysiological insights.
Int J Hematol. 2017 Dec 01;:
Authors: Girelli D, Ugolini S, Busti F, Marchi G, Castagna A
Abstract
Iron deficiency, with or without anemia, is extremely frequent worldwide, representing a major public health problem. Iron replacement therapy dates back to the seventeenth century, and has progressed relatively slowly until recently. Both oral and intravenous traditional iron formulations are known to be far from ideal, mainly because of tolerability and safety issues, respectively. At the beginning of this century, the discovery of hepcidin/ferroportin axis has represented a turning point in the knowledge of the pathophysiology of iron metabolism disorders, ushering a new era. In the meantime, advances in the pharmaceutical technologies are producing newer iron formulations aimed at minimizing the problems inherent with traditional approaches. The pharmacokinetic of oral and parenteral iron is substantially different, and diversities have become even clearer in light of the hepcidin master role in regulating systemic iron homeostasis. Here we review how iron therapy is changing because of such important advances in both pathophysiology and pharmacology.
PMID: 29196967 [PubMed - as supplied by publisher]

Source: International Journal of Hematology - December 1, 2017 Category: Hematology Authors: Girelli D, Ugolini S, Busti F, Marchi G, Castagna A Tags: Int J Hematol Source Type: research